Printer Friendly

SURGIDYNE RECEIVES $350,000 IN ORDERS

 SURGIDYNE RECEIVES $350,000 IN ORDERS
 INVER GROVE HEIGHTS, Minn., April 1 /PRNewswire/ -- Surgidyne, Inc.


(the company) reports receiving a second round of orders totalling over $350,000 from Baxter Healthcare Corporation of Deerfield, Ill.
 The orders are for the company's private label orthopedic postoperative autotransfusion (AT) products developed for Baxter and recently introduced by Baxter to the U.S. hospital market. Key to the system is the lightweight (2 pounds) Vacuum Controller which provides continuous, uninterrupted suction for postoperative wound drainage. The AT system is used following total hip and knee joint replacement surgery. The Vacuum Controller suctions blood through postoperative orthopedic drains into a collection unit. When autotransfusion is desired, the blood is transferred into a blood filter bag. The patient's own blood can then be directly reinfused, while the vacuum system continues to provide continued suction therapy. The company stated that the primary advantages of its system over competitive products is the continuous, controlled suction from drain placement until removal, combined with a closed system for collection and autotransfusion of one or more units of blood without patient line filters that clog, and without potentially dangerous patient line disconnects.
 Baxter's first national introductions of the system were at the annual American Academy of Orthopedic Surgeons Convention in Washington, D.C., Feb. 20-24, and at the Association of Operating Room Nurses annual convention in Dallas, March 17-20, 1992.
 The company estimates that there will be over 500,000 hip and knee surgeries performed in the United States in 1992 that offer potential for use of autotransfusion systems. The compound growth of the hip and knee replacement market exceeds 12 percent per year. Dynamic growth is being seen in the sale of autotransfusion systems as surgeons and patients often prefer the use of autologous blood (the patient's own blood) to homologous (donated blood from blood banks). Autotransfusion eliminates their concerns about infections from blood with AIDS or Hepatitus B virus.
 The company designs, develops, manufactures and markets specialty medical and surgical products. The company's executive offices are located at 9605 West Jefferson, Inver Grove Heights, Minn. 55077.
 The company's stock is traded in the local over-the-counter market.
 -0- 4/1/92
 /CONTACT: Charles B. McNeil of Surgidyne, 612-681-9235/ CO: Surgidyne, Inc. ST: Minnesota IN: MTC SU:


AL -- MN012 -- 3923 04/01/92 13:58 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1992
Words:386
Previous Article:NEG ANNOUNCES INTENT TO COMMENCE RECAPITALIZATION PLAN
Next Article:NISSAN REVEALS 'ALTIMA' NAME FOR ALL-NEW U.S.-BUILT 1993 MID-SIZE SEDAN
Topics:


Related Articles
SURGIDYNE, INC. REPORTS THIRD QUARTER RESULTS
SURGIDYNE ANNOUNCES 1991 TOTAL REVENUES EXCEED $1,000,000
SURGIDYNE REPORTS SECOND QUARTER AND SIX MONTHS PROFIT
SURGIDYNE INC. REPORTS SECOND CONSECUTIVE PROFITABLE YEAR
SURGIDYNE, INC. REPORTS ELECTION OF NEW OFFICERS
Surgidyne, Inc. to Sell Substantially All of Its Assets to Oxboro Medical.
Oxboro Medical to Acquire Surgidyne, Inc. Closed Wound Drainage Business.
Sterion Completes Acquisition of Surgidyne Inc. Closed Wound Drainage Business.
TriVirix Forms Manufacturing Partnership with Sterion.
Sterion Sells Medical Product Business to Aspen Surgical Products.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters